

Improving Diagnoses with the Awesome Power of Yeast Genetics

Aimée M. Dudley, Ph.D.





My lab receives sponsored research funding from Moderna, a company that is developing therapeutics for OTC deficiency. Moderna did not fund any of the research that will be presented in this seminar.

I am a Scientific Advisor with a financial interest in FenoLogica Biosciences.

Who are we and how did we start doing urea cycle disorder research?

What kind of research do we do?

Doctors, patients, and families who participate in clinical research

Yeah, we're that kind of scientist

Pacific Northwest Research Institute

Russell Lo

Michelle Tang, Ph.D.

Pacific Northwest Research Institute

Russell Lo

Gareth Cromie, Ph.D.

Children's National Hospital

Andrea Gropman, M.D.

Nicholas Ah Mew, M.D.

Ljubica Caldovic, Ph.D.

Hiroki Morizono, Ph.D.

OTC is the example... more (in pink) coming soon!

How can genetics give faster and more informative diagnoses?

Let's first talk a little about genetics...

Genetic diseases can be diagnosed by DNA sequencing

New DNA sequencing technologies can:

- shorten diagnostic odysseys
- rapidly diagnose sick newborns
- expand newborn screening
- provide a non-invasive prenatal test (from maternal blood)

A few things to know about your DNA

Each of our genomes is like a really long book of ~6 billion (GATC) letters. Think of it as an instruction manual for how to build and operate a human.

The sequence of a gene is like a sentence in a book

A cat sat on my pillow. ATG CAT GGT CCC CAC GTT TAA

Let's pretend that this sequence is the gene that makes the working version of OTC.

Benign sequence changes do not cause disease

benign		The	cat	sat	on	my	pill	ow.
		TTG	CAT	GGT	CCC	CAC	GTT	TAA

Pathogenic sequence changes have the potential to cause disease

Most sequence changes are <u>Variants of Uncertain Significance</u> (VUS)

Good news! You don't need to remember any of those terms.

What's important:

- some DNA changes are harmless
- some can cause disease
- but for most we just don't know

The scale of this problem is enormous!

60 million of the type of variants that my lab studies could arise in the human population.

59.9 million are currently VUS.

"My, my but you do have a problem- a BIG problem!"

- John Hall, How to Get a Gorilla Out of Your Bathtub

60 million of the type of variants that my lab studies could arise in the human population.

59.9 million are currently VUS.

Which of the 2,000 OTC variants are likely to cause disease?

We can test them all, but not in humans

The Awesome Power of Yeast Genetics

Yeast is a powerful model organism

- We can do experiments faster, cheaper, and more easily than in other systems
- Many biological processes that are important in human cells function the same way in yeast cells, including the urea cycle!

How did Russell test 1,570 variants in OTC?

Comparing activity in yeast to disease presentation in people

Yeast activity > 90% (high) 5%-90% (medium) < 5% (low)

Most early onset male patients have very low activity variants

Most late onset males have low to medium activity variants

Most symptomatic females have very low activity variants

What does this say about a person's genetic risk?

A very important point:

Functional information about genetic variants is only one piece of information that doctors, patients, and families can use to make decisions. 1,356 of the variants in Russell's study do not have patient data

What does this mean?

The variants that are most difficult for geneticists are the ones no one has seen before.

There are a lot of them, and a huge number have the potential to cause the most severe form of the disease.

National Urea Cycle Disorders Foundation

Thank you!

Patients and families that participate in clinical research

PNRI

Gareth A. Cromie, Ph.D. Russell S. Lo Michelle Tang, Ph.D. Martin S. Timour Julee A. Ashmead Kevin Tang Katherine Owens, Ph.D. Children's National Hospital Hiroki Morizono, Ph.D. Ljubica Caldovic, Ph.D. Nicholas Ah Mew, M.D. Andrea Gropman, M.D. University of Washington J. Nathan Kutz, Ph.D.

Funding: NIH/NIGMS award R01 GM13134274

National Institutes of Health

